APA (7th ed.) Citation

JG, F., F, W., L, M., C, F., E, C., GP, N., . . . D, W. (2026). Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 67(3), 416. https://doi.org/10.2967/jnumed.125.270654

Chicago Style (17th ed.) Citation

JG, Fricke, et al. "Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 67, no. 3 (2026): 416. https://doi.org/10.2967/jnumed.125.270654.

MLA (9th ed.) Citation

JG, Fricke, et al. "Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 67, no. 3, 2026, p. 416, https://doi.org/10.2967/jnumed.125.270654.